We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+14.25%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$966M
AUM Growth
+$269M
Cap. Flow
+$319M
Cap. Flow %
33.08%
Top 10 Hldgs %
49.6%
Holding
104
New
32
Increased
25
Reduced
14
Closed
27

Top Buys

Rank Stock Value
1
SNN icon
Smith & Nephew
SNN
+$27.6M
2
RIGL icon
Rigel Pharmaceuticals
RIGL
+$20.3M
3
SIBN icon
SI-BONE Inc
SIBN
+$18.8M
4
NTRA icon
Natera
NTRA
+$14.1M
5
JSPR icon
Jasper Therapeutics
JSPR
+$13.8M

Top Sells

Rank Stock Value
1
CVRX icon
CVRx
CVRX
+$18.6M
2
VCEL icon
Vericel Corp
VCEL
+$16.9M
3
LLY icon
Eli Lilly
LLY
+$14.3M
4
HCA icon
HCA Healthcare
HCA
+$8.29M
5
KRYS icon
Krystal Biotech
KRYS
+$8.09M

Sector Composition

Rank Sector Weight
1 Healthcare 81.2%
2 Consumer Staples 1.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DICE
51
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$4.97M 0.51%
173,447
– –
ENTA icon
52
Enanta Pharmaceuticals
ENTA
$396M
$4.71M 0.49%
116,514
-21,300
-15% -$1.02M
MLYS icon
53
Mineralys Therapeutics
MLYS
$2.39B
$4.28M 0.44%
+273,241
New +$4.6M
PVLA
54
Palvella Therapeutics
PVLA
$2.27B
$4.04M 0.42%
51,686
+39,186
+313% +$4.54M
CERE
55
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$3.78M 0.39%
+155,000
New +$4.55M
ABCM
56
DELISTED
Abcam PLC
ABCM
$3.77M 0.39%
+279,971
New +$4.18M
INSP icon
57
Inspire Medical Systems
INSP
$1.72B
$3.65M 0.38%
15,600
-30,600
-66% -$7.74M
ACAD icon
58
Acadia Pharmaceuticals
ACAD
$4.98B
$3.58M 0.37%
+190,000
New +$3.62M
ANNX icon
59
Annexon
ANNX
$893M
$3.52M 0.37%
+915,400
New +$5.04M
FNA
60
DELISTED
Paragon 28, Inc.
FNA
$3.48M 0.36%
+204,018
New +$3.64M
PHVS icon
61
Pharvaris
PHVS
$2.43B
$2.71M 0.28%
336,900
+26,900
+9% +$237K
KYNB
62
Kyntra Bio
KYNB
$29.1M
$2.42M 0.25%
5,179
+640
+14% +$339K
ANGO icon
63
AngioDynamics
ANGO
$640M
$2.33M 0.24%
+225,000
New +$2.88M
ACRS icon
64
Aclaris Therapeutics
ACRS
$813M
$2.01M 0.21%
+249,000
New +$3.16M
CSII
65
DELISTED
Cardiovascular Systems, Inc.
CSII
$1.89M 0.2%
+95,346
New +$1.65M
AMLX icon
66
Amylyx Pharmaceuticals
AMLX
$2.55B
$1.85M 0.19%
63,214
+12,578
+25% +$437K
PRDS
67
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$1.65M 0.17%
1,250,000
– –
TMDX icon
68
Transmedics
TMDX
$2.8B
$1.44M 0.15%
19,000
-24,500
-56% -$1.69M
RXST icon
69
RxSight
RXST
$252M
$1.33M 0.14%
+80,000
New +$1.13M
AXSM icon
70
Axsome Therapeutics
AXSM
$10.8B
$1.28M 0.13%
20,700
-29,300
-59% -$1.92M
LYRA
71
DELISTED
LYRA THERAPEUTICS INC
LYRA
$1.19M 0.12%
11,848
– –
OBIO icon
72
Orchestra BioMed
OBIO
$253M
$1.18M 0.12%
+60,450
New +$700K
LUNG icon
73
Pulmonx
LUNG
$89.3M
$794K 0.08%
71,000
– –
XLO icon
74
Xilio Therapeutics
XLO
$60.8M
$719K 0.07%
16,210
– –
IMUX icon
75
Immunic
IMUX
$206M
$447K 0.05%
+30,000
New +$557K
1 2
3
4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Soleus Capital Management held 104 positions worth $966M, up 39% from $697M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Soleus Capital Management deployed $319M of net new capital in Q1 2023, opening 32 new positions and adding to 25 existing holdings. Its largest new stake was Smith & Nephew: 970,200 shares worth $27.1M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 97% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Vericel Corp, an estimated $16.9M trimmed.

  • Soleus Capital Management's largest Q1 2023 buy was Smith & Nephew: 970,200 shares worth $27.1M.
  • Soleus Capital Management added most to CVS Health in Q1 2023, an estimated $12.5M increase.
  • Soleus Capital Management's biggest Q1 2023 reduction was Vericel Corp, cutting an estimated $16.9M.
  • Soleus Capital Management fully exited CVRx in Q1 2023, selling an estimated $18.6M.
  • Soleus Capital Management's ten largest holdings make up 50% of its $966M portfolio in Q1 2023.
  • Soleus Capital Management opened 32 new positions and closed 27 in Q1 2023.
  • Soleus Capital Management's portfolio value rose 39% quarter-over-quarter to $966M.

Based on Soleus Capital Management's 13F filing for Q1 2023, filed 15 May 2023.